Indivior Pharmaceuticals — Key Risks
Dangerous Concentration in a Single Product: SUBLOCADE Is 69% of Revenue
SUBLOCADE, a monthly injectable buprenorphine treatment, now accounts for 69% of total net revenues (up from 58% just two years ago). Meanwhile, the company's older oral products like SUBOXONE Film are in structural decline, with market share falling from over 50% in 2018 to just 14.2% in 2025. If SUBLOCADE faces any meaningful competitive, regulatory, or reimbursement setback, there is very little else in the current portfolio to cushion the blow.
A Direct Competitor Now Exists for the Company's Core Product
In 2023, a rival launched BRIXADI, a competing injectable buprenorphine product, directly challenging SUBLOCADE in its own niche. The company also cannot promote SUBOXONE Film in the U.S. due to legal settlement restrictions through 2032. This means Indivior's ability to defend and grow revenue depends almost entirely on out-competing one rival in a single product category.
A Long History of Major Litigation with More Still Pending
Indivior has paid out over $1.2 billion in legal settlements in recent years, covering antitrust claims, DOJ fraud charges, and opioid-related lawsuits. Right now, a large number of dental injury lawsuits claim that SUBOXONE Film caused tooth damage, and UK shareholders have filed securities fraud claims. Insurance coverage for opioid-related liability is explicitly limited by policy exclusions, meaning future adverse judgments could hit the company's finances directly.
Medicaid Cuts Could Directly Shrink the Patient Population
Indivior's products treat opioid use disorder (OUD), a condition disproportionately covered by Medicaid, the government insurance program for lower-income Americans. Congressional budget proposals (specifically referenced as the 2025 OBBBA) could reduce Medicaid eligibility or restrict coverage of higher-cost OUD treatments. Fewer covered patients means fewer prescriptions, directly threatening revenue.
Entire Manufacturing Depends on Third Parties, Often Single Sources
Indivior manufactures almost nothing itself, relying entirely on contract manufacturers. For most products — including the key active ingredient buprenorphine — there is only a single or dual source of supply. If a supplier has a quality failure or compliance problem, finding and qualifying a replacement takes an average of 36 months. A supply disruption of that length could be devastating for a company this dependent on one product.
Leveraged Balance Sheet With Liabilities Exceeding Assets
As of December 31, 2025, Indivior's total liabilities exceed total assets by approximately $100 million, and current liabilities exceed current assets by over $250 million. The company carries a $333 million term loan with tightening financial ratio requirements. If revenue declines — which the company itself flags as likely for SUBOXONE Film in 2026 — the company's ability to meet debt covenants and fund operations could come under real pressure.
FTC and State Oversight Adds Ongoing Legal Risk Through 2030
As part of past settlements, Indivior is bound by a Stipulated FTC Order and a parallel agreement with 41 state attorneys general, both running until 2030. These impose detailed reporting obligations and restrict how Indivior can launch new products or engage in corporate transactions. Violating these orders could trigger criminal contempt charges — an unusually severe consequence compared to the standard regulatory risks most pharmaceutical companies face.